5-MAPDB

Summary

5-MAPDB, also known as 1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine, belongs to the category of entactogenic compounds. It shares structural similarities with substances like 5-APDB and 5-MAPB, both of which produce effects akin to MDMA and are often used for recreational purposes. Extensive research has explored the pharmacological properties of 5-MAPDB, revealing its role as a relatively specific serotonin releaser. However, it exhibits weaker capabilities in releasing other monoamines and acts as an agonist for the 5-HT2 receptor family, much like its predecessors, such as 5-APDB.

Identifiers

IUPAC name
CAS Number	1354631-78-9
PubChem CID	112500533
ChemSpider	52085108
UNII	FS5Z21939Z
Chemical and physical data
Formula	C12H17NO
Molar mass	191.27 g·mol−1

Legality

In June 2013, the United Kingdom implemented a temporary class drug ban on 5-MAPDB, along with nine other associated compounds, even though it had not been previously available as a street drug. The reason behind this preemptive ban was the apprehension that 5-MAPDB could potentially produce effects similar to those of substances like 5-APB, which were already in widespread circulation. There was concern that 5-MAPDB might gain popularity as a recreational drug if not prohibited in advance.

FAQ

• What is 5-MAPDB?
• 5-MAPDB is a chemical compound known as 1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine. It is categorized as an entactogenic drug and is structurally related to substances like 5-APDB and 5-MAPB.
• What are the effects of 5-MAPDB?
• 5-MAPDB is reported to have entactogenic effects, similar to MDMA. Users often describe increased empathy, sociability, and enhanced sensory perception. However, individual experiences may vary.
• Is 5-MAPDB legal?
• The legal status of 5-MAPDB varies by country. It was temporarily classified as a controlled substance in the United Kingdom in June 2013. Laws regarding its legality may change over time, so it’s essential to stay informed about your local regulations.
• Is 5-MAPDB safe to use?
• The safety of 5-MAPDB is not well-documented, and it may carry risks, just like other psychoactive substances. Users should exercise caution, use harm-reduction strategies, and avoid mixing it with other drugs. The long-term health effects are not well understood.
• How is 5-MAPDB typically consumed?
• 5-MAPDB is typically consumed orally in the form of a powder, capsule, or tablet. It can also be insufflated (snorted), but this method is rare.
• What are the risks associated with 5-MAPDB use?
• As with many psychoactive substances, there are potential risks associated with 5-MAPDB use, including but not limited to adverse reactions, addiction, and unknown long-term health effects. Overdosing is also a concern, and users should be aware of proper dosing.
• Can 5-MAPDB be used recreationally?
• 5-MAPDB is often used recreationally for its entactogenic effects. However, due to its legal status and potential risks, users need to exercise responsible and informed use.
• Where can I find more information about 5-MAPDB?
• Information on 5-MAPDB can be found through research studies, online forums, and harm reduction websites. It’s crucial to consult reliable sources and exercise caution when seeking information about this substance.
• Is 5-MAPDB the same as 5-APB or 5-MAPB?
• While these compounds share structural similarities and produce similar effects, they are distinct substances. 5-APB and 5-MAPB are separate compounds from 5-MAPDB, although they all belong to the entactogenic class of drugs.
• What precautions should I take if I plan to use 5-MAPDB?
• If you choose to use 5-MAPDB, it’s essential to:

• Research its effects and potential risks.
• Start with a low dose to assess your tolerance.
• Use in a safe and comfortable environment.
• Avoid mixing with other substances, including alcohol.
• Inform someone you trust about your use.
• Be aware of the legal status in your location.
• Seek medical help if you experience adverse effects.

References

1. Anvisa (2023-07-24). “RDC Nº 804 – Compilation of Substances Entailing Narcotic, Psychotropic, Precursor, and Other Special Control” [Official Resolution No. 804 by the Collegiate Board] (in Brazilian Portuguese). Published in the Diário Oficial da União on 2023-07-25. Archived from the original source until 2023-08-27. Retrieved on 2023-08-27. – This is an official Brazilian document by Anvisa detailing the categorization of controlled substances.
2. Rickli A, Kopf S, Hoener MC, Liechti ME (July 2015). “Pharmacological Profile of Novel Psychoactive Benzofurans” published in the British Journal of Pharmacology, Volume 172, Issue 13, Pages 3412-3425. DOI: 10.1111/bph.13128. PMC 4500375. PMID: 25765500 – This scientific paper explores the pharmacological characteristics of novel psychoactive benzofuran compounds.
3. Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE (November 1993). “Synthesis and Pharmacological Examination of Analogues of 3,4-(Methylenedioxy)amphetamine” published in the Journal of Medicinal Chemistry, Volume 36, Issue 23, Pages 3700-3706. DOI: 10.1021/jm00075a027. PMID: 8246240 – This research paper delves into the synthesis and pharmacological assessment of analogues of a specific amphetamine derivative.
4. “Temporary Class Drug Order Report on 5-6APB and NBOMe Compounds” released by the UK Home Office on 4 June 2013. Retrieved on 2013-07-11 – This report provides information on the temporary classification of specific compounds by the UK Home Office, including 5-6APB and NBOMe compounds.